ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,780.05
-0.21%
US Tech 100
19,666.40
-0.19%
Dow Jones
42,454.12
-0.14%
Brent Oil
78.585
-0.60%
Bitcoin
61,105.36
1.39%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Werewolf Therapeutics Inc (HOWL) Quote

Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL)

NASDAQ
1.81
-0.03
(-1.63%)
Closed October 10 4:00PM
Delayed by 15 minutes
1.81
0.00
( 0.00% )
Pre Market: 7:00AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.81
Bid
1.85
Ask
1.90
Volume
79
0.00 Day's Range 0.00
1.5735 52 Week Range 8.1939
Market Cap
79.101M
Previous Close
1.81
Open
-
Last Trade
79
@
1.75
Last Trade Time
04:15:59
Financial Volume
-
VWAP
-
Average Volume (3m)
167,553
Shares Outstanding
43,702,147
Dividend Yield
-
PE Ratio
-2.12
Earnings Per Share (EPS)
-0.86
Revenue
19.94M
Net Profit
-37.37M

About Werewolf Therapeutics Inc

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
werewolftx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Werewolf Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HOWL. The last closing price for Werewolf Therapeutics was $1.81. Over the last year, Werewolf Therapeutics shares have traded in a share price range of $ 1.5735 to $ 8.1939.

Werewolf Therapeutics currently has 43,702,147 shares outstanding. The market capitalization of Werewolf Therapeutics is $79.10 million. Werewolf Therapeutics has a price to earnings ratio (PE ratio) of -2.12.

Ask ADVFN Intelligence (AI)

HOWL Latest News

More News

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

October 04 2024
GlobeNewswire Inc.

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

September 03 2024
GlobeNewswire Inc.

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

August 08 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 08 2024
Edgar (US Regulatory)

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting – – Encouraging signs of clinical activity at tolerable...

August 08 2024
GlobeNewswire Inc.

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical...

June 25 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 03 2024
Edgar (US Regulatory)

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

-  WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - -  Encouraging single agent clinical...

June 01 2024
GlobeNewswire Inc.

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

May 30 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.24-11.70731707322.052.051.751045791.92177641CS
4-0.39-17.72727272732.22.4521.751492412.07940961CS
12-0.98-35.12544802872.792.981.661675532.19828673CS
26-3.55-66.23134328365.366.891.662142833.21617414CS
52-0.27-12.98076923082.088.19391.57354071033.50218082CS
156-14.24-88.72274143316.0517.951.392316684.14408383CS
260-16.4-90.060406370118.2123.991.392154124.84966847CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZENAZenaTech Inc
$ 3.27
(84.75%)
8.99M
NIVFNewGenIvf Group Ltd
$ 0.9649
(60.90%)
3.99M
LUXHLuxUrban Hotels Inc
$ 0.0727
(43.96%)
35.7M
JTAIJet AI Inc
$ 0.1004
(22.89%)
21.87M
MBRXMoleculin Biotech Inc
$ 2.98
(22.63%)
4
NCNCnoco noco Inc
$ 0.0892
(-23.56%)
247.96k
OSTOstin Technology Group Company Ltd
$ 0.302
(-13.71%)
2
CTCXCarmell Corporation
$ 0.3303
(-13.69%)
114.53k
TSLRGraniteShares ETF Trust GraniteShares
$ 15.231
(-13.41%)
82.7k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 9.91
(-13.15%)
10.6M
LUXHLuxUrban Hotels Inc
$ 0.0727
(43.96%)
35.7M
JTAIJet AI Inc
$ 0.1004
(22.89%)
21.87M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 9.91
(-13.15%)
10.6M
ZENAZenaTech Inc
$ 3.27
(84.75%)
8.99M
CETXCemtrex Inc
$ 0.5528
(17.87%)
8.78M

HOWL Discussion

View Posts
Monksdream Monksdream 1 month ago
HOWL under $3
👍️0
Monksdream Monksdream 3 months ago
HOWL under $3
👍️0
Monksdream Monksdream 5 months ago
HOWL under $10
👍️0
Monksdream Monksdream 9 months ago
HOWL new 52 week high
👍️0
Pt3 Pt3 11 months ago
Yea your gap and trapped make me buy caud instead of this
👍️0
TheFinalCD TheFinalCD 11 months ago
HOWL todays algo patented Gap & Trap on Phase #1 news
👍️0
TheFinalCD TheFinalCD 11 months ago
Werewolf Therapeutics soars 52% premarket after presentsing preliminary monotherapy data from Phase 1/1b clinical trial establishing proof of mechanism for WTX-124$HOWL#AInvest #Ainvest_Wire #trade #source #wallstreet
View more: https://t.co/aTzfU7GqUS pic.twitter.com/rClSWzl2IS— AInvest Wire (@Ainvest_Wire) November 3, 2023
👍️0
TheFinalCD TheFinalCD 11 months ago
$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL
👍️0
tw0122 tw0122 11 months ago
$3 + otw Halloween is here give it a HOWL
👍️0
The Night Stalker The Night Stalker 1 year ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
👍️0
The Night Stalker The Night Stalker 1 year ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
👍️0
The Night Stalker The Night Stalker 1 year ago
dip
👍️0
The Night Stalker The Night Stalker 1 year ago
dip
👍️0
The Night Stalker The Night Stalker 1 year ago
watching
👍️0
The Night Stalker The Night Stalker 1 year ago
soon
👍️0
The Night Stalker The Night Stalker 1 year ago
insert dd
👍️0
The Night Stalker The Night Stalker 1 year ago
can be big
👍️0
The Night Stalker The Night Stalker 1 year ago
wow
👍️0
The Night Stalker The Night Stalker 1 year ago
wow
👍️0
The Night Stalker The Night Stalker 1 year ago
hold
👍️0
The Night Stalker The Night Stalker 1 year ago
slow
👍️0
The Night Stalker The Night Stalker 1 year ago
slow
👍️0
The Night Stalker The Night Stalker 1 year ago
agreed
👍️0
The Night Stalker The Night Stalker 1 year ago
like thiks
👍️0
The Night Stalker The Night Stalker 1 year ago
off radar
👍️0
The Night Stalker The Night Stalker 1 year ago
catchy name
👍️0
The Night Stalker The Night Stalker 1 year ago
catchy name
👍️0
surf1944 surf1944 1 year ago
https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion
👍️0
Mr. Zen Mr. Zen 2 years ago
Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

“These promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. “This morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”
👍️0
makinezmoney makinezmoney 2 years ago
$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL
👍️0
Makk1 Makk1 2 years ago
Good call here, looking very good
👍️0
makinezmoney makinezmoney 2 years ago
$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL
👍️0
bobbo5 bobbo5 2 years ago
I agree and it looks like share price has been moving up this past week
👍️0
dia76ca dia76ca 2 years ago
Very interesting company. I like it's chances.
👍️0

Your Recent History

NASDAQ
HOWL
Werewolf Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved